Mismatched Tech And Demand Behind Korea’s Slow Pharma AI Progress
'Trial And Error' Process
Executive Summary
The new head of South Korea’s AI Drug Development Support Center talks about the country’s activities and market trends in the field, why the otherwise tech-savvy country is still lagging and what is needed to boost collaboration and the availability of big data.
You may also be interested in...
New Korea Commission Needs Status To Function As Control Tower: Industry
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
Global Health Leaders Highlight Pandemic Preparedness
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Are Korean Biopharma Alliances Recovering After Gloomy Year?
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.